The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) is a huge mover today! About 235,194 shares traded hands. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 153.09% since April 5, 2016 and is uptrending. It has outperformed by 151.13% the S&P500.
The move comes after 6 months positive chart setup for the $1.03 billion company. It was reported on Nov, 7 by Barchart.com. We have $54.44 PT which if reached, will make NASDAQ:AERI worth $576.80 million more.
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Ratings Coverage
Out of 10 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 10 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aerie Pharmaceuticals has been the topic of 20 analyst reports since August 7, 2015 according to StockzIntelligence Inc. The rating was maintained by Cantor Fitzgerald with “Buy” on Thursday, September 15. RBC Capital Markets maintained Aerie Pharmaceuticals Inc (NASDAQ:AERI) rating on Thursday, September 15. RBC Capital Markets has “Outperform” rating and $55 price target. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) earned “Buy” rating by Stifel Nicolaus on Thursday, September 17. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) earned “Outperform” rating by RBC Capital Markets on Wednesday, November 4. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, October 6. The company was initiated on Wednesday, September 14 by Raymond James. Cantor Fitzgerald maintained it with “Buy” rating and $40 target price in Thursday, September 17 report. The company was reinitiated on Friday, June 3 by Cantor Fitzgerald. The rating was initiated by JMP Securities on Wednesday, September 9 with “Market Outperform”. As per Thursday, September 15, the company rating was maintained by Needham.
According to Zacks Investment Research, “Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s lead Dual- Action product and Triple-Action products are under developmental stages. Aerie Pharmaceuticals, Inc. is headquartered in Bedminster, New Jersey.”
Insitutional Activity: The institutional sentiment increased to 1.67 in Q2 2016. Its up 0.28, from 1.39 in 2016Q1. The ratio is positive, as 11 funds sold all Aerie Pharmaceuticals Inc shares owned while 22 reduced positions. 9 funds bought stakes while 46 increased positions. They now own 26.15 million shares or 2.97% more from 25.39 million shares in 2016Q1.
Essex Lc owns 107,700 shares or 0.32% of their US portfolio. Metropolitan Life Ins Ny reported 17,893 shares or 0% of all its holdings. Royal Savings Bank Of Canada has 0% invested in the company for 99,451 shares. Moreover, Blackrock Institutional Trust Na has 0% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 628,844 shares. Wall Street has invested 0.14% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Credit Suisse Ag holds 0% or 36,693 shares in its portfolio. Leisure Capital holds 0.51% or 25,831 shares in its portfolio. Jpmorgan Chase & Communications has 0% invested in the company for 284 shares. Wasatch Advsrs holds 0% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 14,809 shares. State Board Of Administration Of Florida Retirement System has 24,578 shares for 0% of their US portfolio. Granite Point Cap Mngmt Limited Partnership has 0.42% invested in the company for 56,225 shares. The New York-based Tiaa Cref Inv Management Ltd Liability Corporation has invested 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Legal And General Grp Incorporated Public Limited Com accumulated 3,836 shares or 0% of the stock. Rice Hall James & Assocs Limited Com accumulated 0.16% or 158,932 shares. Ameriprise owns 156,729 shares or 0% of their US portfolio.
Insider Transactions: Since July 22, 2016, the stock had 1 insider buy, and 0 sales for $4.38 million net activity. Foresite Capital Management II – LLC had bought 250,000 shares worth $4.38M on Friday, July 22.
More news for Aerie Pharmaceuticals Inc (NASDAQ:AERI) were recently published by: Fool.com, which released: “Why Aerie Pharmaceuticals Is Soaring 54% Today” on September 15, 2016. Businesswire.com‘s article titled: “Aerie Pharmaceuticals to Host Investor Day on October 5, 2016” and published on September 16, 2016 is yet another important article.
AERI Company Profile
Aerie Pharmaceuticals, Inc., incorporated on June 22, 2005, is a clinical-stage pharmaceutical company. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. The Company’s product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.